Welcome to our dedicated page for Cytodyn news (Ticker: CYDY), a resource for investors and traders seeking the latest updates and insights on Cytodyn stock.
CytoDyn Inc (CYDY) is a clinical-stage biotechnology company advancing leronlimab, an investigational CCR5-targeting therapy with applications in oncology, inflammation, and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases and verified news covering clinical trial results, FDA communications, and research collaborations. Users gain access to critical updates about leronlimab's development across multiple therapeutic areas, including ongoing studies in metastatic cancers and inflammatory conditions.
The resource emphasizes CytoDyn's progress in resolving historical challenges and establishing robust clinical protocols. Key content categories include trial design updates, partner announcements with organizations like Syneos Health, and regulatory pathway developments. All materials maintain strict adherence to factual reporting standards.
For those monitoring biopharmaceutical innovation, this page serves as a reliable source for tracking CytoDyn's evidence-based approach to drug development. Bookmark this hub to stay informed about new developments in CCR5-targeted therapies and the company's evolving clinical pipeline.
CytoDyn (OTCQB: CYDY) announced a $30 million funding commitment from Yorkville Advisors Global dated November 3, 2025.
Under the agreement CytoDyn may sell, at its discretion, up to $30 million of common stock to Yorkville over the next 36 months; Yorkville is obligated to purchase amounts the company elects to sell. The company controls timing of all sales, there are no warrants, derivatives, or other share classes tied to the arrangement, and there are no minimum use requirements or operating restrictions. CytoDyn said it intends to use the commitment to further develop leronlimab programs, including research on upregulating PD-L1. Additional terms are disclosed in CytoDyn’s Form 8-K filed November 3, 2025.
CytoDyn (OTCQB: CYDY) announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX investor conference in San Diego from October 19–21, 2025.
The presentation is scheduled for Tuesday, October 21, 2025 at 9 a.m. PDT and will be available via webcast. Topics noted include the company’s development strategy for leronlimab, a CCR5‑targeting monoclonal antibody with programs in triple‑negative breast cancer and metastatic colorectal cancer. Mr. Hoffman is available for one‑on‑one investor meetings; meeting requests go to CytoDyn@russopartnersllc.com.
CytoDyn (CYDY) released a shareholder letter highlighting significant progress in advancing leronlimab for oncology treatment. The company announced promising survival data in Metastatic Triple-Negative Breast Cancer (mTNBC), with survival rates of 35.7%, 21.4%, 17.9%, and 17.9% at years 1-4 respectively.
Key developments include the appointment of Robert E. Hoffman as CFO, closure of SEC and DOJ investigations, and advancement in clinical trials. The company revealed a novel mechanism of action for leronlimab that induces PD-L1 expression, creating potential synergy with immune checkpoint inhibitors. A Phase II proof of concept protocol for PD-L1-negative mTNBC patients is planned, alongside an Expanded Access Protocol for second-line mTNBC treatment.
The company is also progressing in metastatic Colorectal Cancer trials with five sites initiated and more being onboarded.
CytoDyn (OTCQB: CYDY) will present significant findings on leronlimab's effectiveness in treating metastatic triple-negative breast cancer (mTNBC) at the AACR Special Conference in Montreal. The company's retrospective analysis of 28 patients revealed that leronlimab, when administered at doses >525mg/week, induced PD-L1 expression in 88% of patients.
Key clinical findings showed that 5 out of 5 patients who received both leronlimab and immune checkpoint inhibitors (ICIs) remain alive after approximately 60 months of treatment. The study demonstrated that 18% of heavily pretreated mTNBC patients survived after a median of ~60 months when treated with CCR5 inhibition combined with ICI therapy.
The research suggests leronlimab could potentially enhance the effectiveness of checkpoint inhibitors in treating solid tumors, particularly in cases previously resistant to such treatments.
CytoDyn (OTCQB: CYDY), a clinical-stage oncology company, will present research findings on its lead drug leronlimab at the AACR Special Conference on Cancer Immunity from September 24-27, 2025, in Montreal. The company's Lead Consultant, Dr. Richard Pestell, will deliver both poster and oral presentations focusing on leronlimab's effects on metastatic triple-negative breast cancer (TNBC).
The research suggests that leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, may convert 'cold' tumors to 'hot' tumors, potentially enhancing responsiveness to checkpoint inhibitors. This mechanism could have broad implications for treating solid tumors with limited treatment options.
CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, has announced a schedule change for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company's CFO, Robert E. Hoffman, will now present on Wednesday, September 10, 2025, at 9:00 AM EDT in New York City.
The presentation will showcase CytoDyn's progress with leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, which shows therapeutic potential across multiple indications. One-on-one meetings with management will be available throughout the conference, which runs from September 8-10, 2025.
CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company's CFO, Robert E. Hoffman, will present on September 10 at 1:30 p.m. EDT at the Lotte New York Palace Hotel.
Leronlimab, the company's lead candidate, is a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with potential applications across multiple indications. The presentation will be available via webcast, and management will be available for one-on-one meetings with conference attendees.
CytoDyn (OTCQB: CYDY) has announced promising survival data for leronlimab in treating metastatic colorectal cancer (mCRC). The clinical findings showed that 3 out of 5 patients treated with leronlimab achieved at least a partial response, with one patient achieving complete response and surviving for five years.
Dr. Benjamin Weinberg from Georgetown University will present these results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona. The data comes from patients treated under a compassionate use protocol and demonstrates both a favorable safety profile and potential clinical benefits. The company is currently conducting a Phase II trial in patients with relapsed/refractory microsatellite stable CRC, with the first patient already dosed.
Additionally, CytoDyn reported evidence of leronlimab's potential as a "priming" agent for cancer patients with low PD-L1 levels who were previously unresponsive to checkpoint inhibitors, showing particular promise in metastatic triple-negative breast cancer (mTNBC) treatment.
CytoDyn (OTCQB: CYDY) has initiated dosing in its Phase II clinical trial evaluating leronlimab for relapsed/refractory microsatellite stable colorectal cancer (CRC). The trial, conducted in partnership with Syneos Health across eight clinical sites, is led by Dr. Ben Weinberg from Georgetown University. According to WHO data, colorectal cancer represents the third most common cancer globally, with approximately 1.9 million new cases and 900,000 deaths annually.
The study builds on CytoDyn's previous research showing potential clinical benefits of leronlimab in relapsed CRC patients and aims to evaluate its mechanism of action in solid tumor oncology. The company's strategy is influenced by promising survival rates observed in prior metastatic triple-negative breast cancer studies.
FAQ
What is the current stock price of Cytodyn (CYDY)?
What is the market cap of Cytodyn (CYDY)?
